Gates Foundation announced funds to develop COVID-19 vaccines and increase access in low-income countries
On Nov. 12, 2020, the Bill & Melinda Gates Foundation announced new commitments totaling $70 million to global…
Vaxart announced additional data from Hamster Challenge Study of its oral COVID-19 vaccine
On Nov. 12, 2020 Vaxart announced additional results from its Hamster Challenge Study. The study evaluated Vaxartï¾’s recombinant…
CIRM Board approved four new clinical trials
On Nov.12, 2020, the governing Board of the California Institute for Regenerative Medicine (CIRM) approved four new clinical…
Wren Laboratories launched saliva-based PCR COVID-19 test
On Nov. 12, 2020, Wren Laboratories announced that it had been granted an emergency use authorization by the…
Early mutation in SARS-CoV-2 virus in Europe led to its domination world wide
On Nov. 12, 2020, a study published in Science by a team of researchers in the U.S. and…
Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2
On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…
Treatments for people with early COVID-19 infection urgent research focus
On Nov. 11, 2020, National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., and…
COVID-19 immunity may last six months or more
On Nov. 11, 2020, Howard Hughes Medical Institute Investigator Michel Nussenzweig and his team reported that people who…
DSMB analysis recommended continuance of P3 COVID-19 ARDS trial
On Nov. 11, 2020, Mesoblast announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with…
COVISHIELD completed enrollment of phase III clinical trials under partnership of ICMR and Serum Institute
On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced…
Mateon and Windlas Biotech announced agreement to commercialize ARTIVEDA against COVID-19
On Nov. 11, 2020, Mateon Therapeutics announced an agreement with Windlas Biotech of India to commercialize ARTIVeda. ARTIVeda…
Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
Largest set of mammalian genomes revealed species at risk of extinction
On Nov. 11, 2020, An international team of researchers with an effort called the Zoonomia Project announced that…
Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
Cardinal Health partnered with CDC to support vaccine access for pharmacies
On Nov. 11, 2020, Cardinal Health announced it had reached an agreement with the Centers for Disease Control…
Data showed SARS-CoV-2 reactive T Cells are associated with protection from COVID-19 was published
On Nov. 10, 2020, Oxford Immunotec announced the release of data from a prospective cohort study in keyworkers…
CureVac published detailed interim phase 1 data of its COVID-19 vaccine candidate, CVnCoV
On Nov. 10, 2020, CureVac announced publication of detailed interim Phase 1 data, following the reporting of positive…
Medigen Vaccines and BlueWillow Biologics partnered to Develop intranasal vaccine for SARS-COV-2
On Nov. 19, 2020, Medigen Vaccine Biologics and BlueWillow Biologics announced a partnership to develop S-2P-NE-01, a nasal…
ImmunityBio, NantKwest announced positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose study
On Nov. 10, 2020, ImmunityBio and NantKwest, a clinical-stage, natural killer cell-based therapeutics company, announced they had administered…
Altimmune added Lonza as manufacturing partner for supply of AdCOVIDï¾™ vaccine candidate for COVID-19
On Nov. 10, 2020, Altimmune announced an agreement with Lonza for the manufacturing of AdCOVIDï¾™, Altimmuneï¾’s next-generation, single-dose…
TB Quat Disinfectant Ready-to-Use Cleaner from 3M approved by EPA for use against SARS-CoV-2
On Nov. 10, 2020, 3M announced that its TB Quat Disinfectant Ready-to-Use Cleaner had been approved by the…
BD announced Canadian Government order of 76 million portable, rapid point-of-care antigen tests to detect SARS-CoV-2
On Nov. 10, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the…
Biotechnology | HIV | Life Science News | NIH | Therapeutics
Long-acting injectable drug prevented HIV in cisgender women
On Nov. 9, 2020, the NIH reported that a pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form…
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
On Nov. 9, 2020, a National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of…
Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19
On Nov. 9, 2020, a study published in JAMA reported the effect of hydroxychloroquine on clinical status at…
Ultragenyx announced plans to build large-scale gene therapy manufacturing facility for rare diseases
On Nov. 9, 2020, Ultragenyx announced that it planned to build a new large-scale gene therapy manufacturing facility…
Lilly’s neutralizing antibody bamlanivimab received FDA emergency use authorization for treatment of recently diagnosed COVID-19
On Nov. 9, 2020, the FDA granted Emergency Use Authorization (EUA) for Eli Lilly’s investigational neutralizing antibody bamlanivimab…
EUROIMMUN launched quantitative ELISA to measure SARS-CoV-2 antibodies against viral S1 protein
On Nov. 9, 2020, PerkinElmer announced that EUROIMMUN, a PerkinElmer company, had launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG)…
Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
Corvus completed enrollment in phase 1 study of CPI-006 for patients with COVID-19
On Nov. 9, 2020, Corvus Pharmaceuticals announced that it had completed patient enrollment in its Phase 1 study…